DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention."
The study demonstrated a gain in quality of life for Impella patients over the current standard of care, the intra-aortic balloon pump (IABP), at an incremental cost-effectiveness ratio (ICER) of $39,389/QALY (Quality Adjusted Life Year), well below the $100,000/QALY threshold commonly used in the United States or the $50,000/QALY threshold of dialysis.
PROTECT II was the first multicenter, randomized trial comparing non-emergent use of hemodynamic support in patients with depressed left ventricular function and complex anatomy that analyzed both the clinical and economic benefits of hemodynamic support. The clinical trial outcomes data and actual billing data from patients were modeled over ten years using a Markov Model to derive the ICER/QALY."This study indicates that new, minimally invasive technologies like Impella provide the opportunity for increased quality care and shared savings opportunities for all stakeholders. As the heart failure population proliferates, decision-makers will need to understand and balance the short-term costs of procedures versus the long-term costs for ongoing care," said David Gregory, MPA, FACHE, author of the study and Executive Vice President and Partner, Presscott Associates - A Division of ParenteBeard, LLC. "We are very excited about the continued expansion of compelling cost-effectiveness data for the Impella platform, which helps providers and payers navigate the evolving landscape of health care reform," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. The American Health & Drug Benefits ( AHDB) is an independent, peer-reviewed journal founded in 2008 on the concept that health and drug benefits have undergone a transformation: the econometric value of a therapy is currently of equal importance to clinical outcomes as it is to serving as the basis for coverage decisions and benefit designs. The publication of this PROTECT II Cost Effectiveness study is one of several published or presented data sets from 2012-2013 that all demonstrate the cost effectiveness of Impella.